$Eli Lilly(LLY)$ $Novo-Nordisk

Bullish Factors:Strong Performance:

1. Companies like Eli Lilly (LLY) and Novo Nordisk (NVO) have seen significant stock price increases (90% and 80% respectively) over the past two years, indicating strong market performance and investor confidence.

2. Market Demand: The increasing demand for effective weight-loss solutions provides a growing market for these companies.

3. Innovation: Hims' plan to offer weight-loss drugs at a significant discount compared to competitors like Wegovy indicates potential for disruption and market share gains.

Considerations:

1. Valuation: High stock prices may reflect current market optimism, potentially limiting immediate upside.

2. Regulatory Risks: The pharmaceutical industry faces stringent regulatory scrutiny, which can impact product approval and market dynamics.

3. Competitive Landscape: The entry of new players and pricing strategies can affect market dynamics and profitability.

LLY Beats vs. NVO Misses:Which Weight Loss Drug Do You Favor?

Eli Lilly expects fiscal year revenue to be between $45.4 billion and $46.6 billion, up from the previous forecast of $42.4 billion to $43.6 billion. Eli Lilly's stock surged 10% in pre-market trading. Novo Nordisk (NVO) stock tumbled Wednesday after the Danish drugmaker reported a rare sales miss. ------------ Which weight loss drug company is a better buy?

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":310492549820488,"tweetId":"310492549820488","gmtCreate":1716813188336,"gmtModify":1716813195632,"author":{"id":4088220260028080,"idStr":"4088220260028080","authorId":4088220260028080,"authorIdStr":"4088220260028080","name":"STLoke","avatar":"https://static.tigerbbs.com/69d7e7705000646320fe426fccb39c93","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":8,"crmLevelSwitch":1,"currentWearingBadge":{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","individualDisplayEnabled":0},"individualDisplayBadges":[],"fanSize":66,"starInvestorFlag":false},"themes":[{"themeId":"3ba18faeb8364f42b810a81bee429b4d","categoryId":"7a15628ce2174325bddc6229505e0d70","name":"LLY Beats vs. NVO Misses:Which Weight Loss Drug Do You Favor?","type":0,"rnLink":"https://laohu8.com/RN?name=RNTheme&page=/theme/detail&rndata={\"themeId\":3ba18faeb8364f42b810a81bee429b4d}&rnconfig={\"headerBarHidden\": true}","description":"Eli Lilly expects fiscal year revenue to be between $45.4 billion and $46.6 billion, up from the previous forecast of $42.4 billion to $43.6 billion. Eli Lilly's stock surged 10% in pre-market trading.\nNovo Nordisk (NVO) stock tumbled Wednesday after the Danish drugmaker reported a rare sales miss.\n------------\nWhich weight loss drug company is a better buy?","image":"https://community-static.tradeup.com/news/96ede51e656d3728375f75b1fee3f8e4"}],"images":[],"coverImages":[],"html":"<html><head></head><body><a href=\"https://ttm.financial/S/LLY\">$Eli Lilly(LLY)$ </a><a href=\"https://ttm.financial/S/NVO\">$Novo-Nordisk A/S(NVO)$ </a>&nbsp;\nBullish Factors:Strong Performance:&nbsp;\n1. Companies like Eli Lilly (LLY) and Novo Nordisk (NVO) have seen significant stock price increases (90% and 80% respectively) over the past two years, indicating strong market performance and investor confidence.\n2. Market Demand: The increasing demand for effective weight-loss solutions provides a growing market for these companies.\n3. Innovation: Hims' plan to offer weight-loss drugs at a significant discount compared to competitors like Wegovy indicates potential for disruption and market share gains.\nConsiderations:\n1. Valuation: High stock prices may reflect current market optimism, potentially limiting immediate upside.\n2. Regulatory Risks: The pharmaceutical industry faces stringent regulatory scrutiny, which can impact product approval and market dynamics.\n3. Competitive Landscape: The entry of new players and pricing strategies can affect market dynamics and profitability.&nbsp;</body></html>","htmlText":"<html><head></head><body><a href=\"https://ttm.financial/S/LLY\">$Eli Lilly(LLY)$ </a><a href=\"https://ttm.financial/S/NVO\">$Novo-Nordisk A/S(NVO)$ </a>&nbsp;\nBullish Factors:Strong Performance:&nbsp;\n1. Companies like Eli Lilly (LLY) and Novo Nordisk (NVO) have seen significant stock price increases (90% and 80% respectively) over the past two years, indicating strong market performance and investor confidence.\n2. Market Demand: The increasing demand for effective weight-loss solutions provides a growing market for these companies.\n3. Innovation: Hims' plan to offer weight-loss drugs at a significant discount compared to competitors like Wegovy indicates potential for disruption and market share gains.\nConsiderations:\n1. Valuation: High stock prices may reflect current market optimism, potentially limiting immediate upside.\n2. Regulatory Risks: The pharmaceutical industry faces stringent regulatory scrutiny, which can impact product approval and market dynamics.\n3. Competitive Landscape: The entry of new players and pricing strategies can affect market dynamics and profitability.&nbsp;</body></html>","text":"$Eli Lilly(LLY)$ $Novo-Nordisk A/S(NVO)$ Bullish Factors:Strong Performance: 1. Companies like Eli Lilly (LLY) and Novo Nordisk (NVO) have seen significant stock price increases (90% and 80% respectively) over the past two years, indicating strong market performance and investor confidence. 2. Market Demand: The increasing demand for effective weight-loss solutions provides a growing market for these companies. 3. Innovation: Hims' plan to offer weight-loss drugs at a significant discount compared to competitors like Wegovy indicates potential for disruption and market share gains. Considerations: 1. Valuation: High stock prices may reflect current market optimism, potentially limiting immediate upside. 2. Regulatory Risks: The pharmaceutical industry faces stringent regulatory scrutiny, which can impact product approval and market dynamics. 3. Competitive Landscape: The entry of new players and pricing strategies can affect market dynamics and profitability.","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/310492549820488","repostId":0,"isVote":1,"tweetType":1,"viewCount":573,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["LLY","NVO"],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":843,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/310492549820488"}